Real-world treatment patterns and associated progression-free survival in relapsed/refractory multiple myeloma among US community oncology practices-Reference-Cited by-同舟云学术

Real-world treatment patterns and associated progression-free survival in relapsed/refractory multiple myeloma among US community oncology practices

Published:2016-06-16 Issue:7 Volume:9 Page:707-717
ISSN:1747-4086
Container-title:Expert Review of Hematology
language:en
Short-container-title:Expert Review of Hematology

Author:

Jagannath Sundar¹,Roy Anuja²,Kish Jonathan³,Lunacsek Orsolya⁴,Globe Denise²,Eaddy Michael⁴,Kuriakose Emil T.²,Willey Joanne⁴,Butler-Bird Stephanie⁴,Siegel David⁵

Affiliation:

1. Tisch Cancer Institute/Multiple Myeloma Program, Mt. Sinai Cancer Institute, New York, NY, USA

2. Global Market Access & Policy, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

3. Formerly with Global Health Economics and Outcomes Research, Xcenda, Palm Harbor, FL, USA

4. Global Health Economics and Outcomes Research, Xcenda, Palm Harbor, FL, USA

5. John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA

Funder

Novartis Pharmaceuticals Corporation

Publisher

Informa UK Limited

Subject

Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/17474086.2016.1195254

Reference21 articles.

1. National Cancer Institute (NCI). Surveillance Epidemiology and End Results (SEER). Myeloma: SEER Stat Fact Sheets. [cited 2015 Jul 31]. Available from: http://seer.cancer.gov/statfacts/html/mulmy.html

2. Treatment options for relapsed and refractory multiple myeloma

3. Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy

4. Clinical Course of Patients With Relapsed Multiple Myeloma

5. National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology. Multiple Myeloma v 4; 2015.

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Characteristics and Outcomes of Patients With Relapsed/Refractory Multiple Myeloma After Exposure to Lenalidomide in First Line of Therapy: A Single Center Database Review in Greece;Clinical Lymphoma Myeloma and Leukemia;2024-07

2. Assessment of prolonged proteasome inhibition through ixazomib‐based oral regimen on newly diagnosed and first‐relapsed multiple myeloma: A real‐world Chinese cohort study;Cancer Medicine;2024-04-30

3. An Epidemiology Model for Estimating the Numbers of US Patients With Multiple Myeloma by Line of Therapy and Treatment Exposure;Value in Health;2022-12

4. Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial;The Lancet Haematology;2022-11

5. The role of E3 ubiquitin ligase in multiple myeloma: potential for cereblon E3 ligase modulators in the treatment of relapsed/refractory disease;Expert Review of Proteomics;2022-06-03